4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow SciClone Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ta1 for Sepsis Thymosin alpha 1, Placebo - Sepsis | Phase 3 | Completed | Sun Yat-sen University | 1106 | 2016-09-06 | 2023-04-10 |
| Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a - Chronic Hepatitis C | Phase 3 | Completed | sigma-tau i.f.r. S.p.A. | 552 | 2004-12-01 | 2010-08-10 |
| Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-05-01 | 2008-01-15 |
| Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-04-01 | 2008-01-15 |
Hepatitis C, Chronic (3) · Hepatitis C (2) · Liver Cirrhosis (1) · Sepsis (1)
Thymalfasin (4) · peginterferon alfa-2a (3) · Ribavirin (1)
Puerto Rico (2) · United States (2) · China (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1)
Guan Xiangdong, M. D (1) · Mario Rizzetto, MD (1)
PMID 17495242, PMID 20549321, PMID 22233415, PMID 23045964, PMID 23327199, PMID 39814420, PMID 42164588
2004 (1)